Physician profile
Donald Carson
NPI 1245595040
$8,411.04
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,448 · 2020: $1,522 · 2021: $2,326 · 2022: $1,981 · 2023: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $133.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,100.32 | 2019-2022 | |
| Novo Nordisk INC | $1,004.42 | 2019-2022 | |
| Abbvie INC. | $670.58 | 2021-2023 | Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $578.90 | 2019-2022 | |
| Lilly USA, LLC | $501.82 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.10 | 2019-2023 | Jardiance |
| Allergan, INC. | $383.23 | 2019-2020 | |
| Amgen INC. | $373.12 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $345.08 | 2019-2022 | |
| Amarin Pharma, INC. | $331.93 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $321.46 | 2021-2022 | |
| Glaxosmithkline, LLC. | $312.44 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $245.06 | 2019-2023 | Seglentis |
| Merck Sharp & Dohme LLC | $238.18 | 2019-2022 | |
| Astellas Pharma US INC | $139.48 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.